Characteristics of the study populations.
| Patients Treated with MTX† | Patients not Treated with MTX, Laboratory Testing Available, n = 286 | ||
|---|---|---|---|
| Laboratory Testing Available, n = 198 | No Laboratory Testing Available, n = 104 | ||
| Age, yrs, mean (SD) | 12.0 (4.9) | 11.9 (5.4) | 13.0 (4.7) |
| Disease duration, yrs, mean (SD) | 4.9 (4.0) | 4.8 (5.0) | 4.7 (2.9) |
| Race, no. (%) | |||
| African American | 7 (4) | 3 (3) | 20 (7) |
| Caucasian | 175 (89) | 98 (94) | 250 (87) |
| Other | 6 (3)* | — | 6 (2) |
| Unknown | 6 (3) | 3 (3) | 10 (3) |
| Gender, no. (%) | |||
| Male | 42 (21) | 25 (24) | 98 (34) |
| Female | 155 (79) | 79 (76) | 188 (66) |
| JRA onset type, no. (%) | |||
| Pauciarticular | 57 (29) | 25 (24) | 183 (64) |
| Polyarticular | 116 (59) | 67 (65) | 73 (26) |
| Systemic | 24 (12) | 11 (11) | 29 (10) |
| JIA subtypes, no. (%) | |||
| Enthesitis related | 1 (0.5) | 1 (1) | 4 (1) |
| Extended oligoarticular | 20 (10) | 13 (13) | 14 (5) |
| Persistent oligoarticular | 38 (19) | 11 (10) | 159 (56) |
| Polyarticular RF− | 100 (51) | 58 (57) | 70 (25) |
| Polyarticular RF+ | 13 (7) | 9 (9) | 7 (2) |
| Psoriatic | 1 (0.5) | — | 2 (1) |
| Systemic | 24 (12) | 11 (10) | 29 (10) |